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Abstract The definitions of bipolar-I (BP-I) and bipolar-
II (BP-II) disorders are currently under revision by the
APA and by the WHO. We provide evidence of a revised
set of criteria for bipolar disorders and major depressive
disorder (MDD) which could serve to strengthen the con-
struct and predictive validity of both disorders and enable
more incisive studies of treatments and courses of both
disorders. In the diagnostic Bridge Study of 5,635 patients
with major depressive episodes from 18 countries (Europe,
North Africa, Near East and Far East) leading psychiatrists
in each country assessed a pre-specified group of symp-
toms, illness course, family history and duration of epi-
sodes; these data allowed tests of several definitions of
bipolarity. The primary revised specifier diagnosis of BP-I
disorder included manic episodes based on an additional
category A criterion (increased activity/energy) and did not
apply any exclusion criteria. The revised BP-II disorders
included hypomanic episodes of 1–3 days. Family history
and illness course validators (history of mania/hypomania
among first degree relatives, 2 or more lifetime episodes
and first symptoms having occurred before age 30) dis-
criminated clearly between patients with bipolar-I or
bipolar-II disorders meeting bipolarity specifier criteria and
those with MDD. Specifier definitions provided better
discrimination between MDD and the two bipolar sub-
groups. Patterns of concurrent comorbidities also differed
significantly between patients meeting criteria for MDD
compared with those meeting bipolar specifier criteria.
Comorbidity patterns differed between bipolar-I and
bipolar-II patients. This study provides evidence for the
validity of modified (specifier) BP-I and BP-II definitions
that incorporate illness course and family history which
reduce ambiguities of major depressive episodes between
bipolar-I and bipolar-II disorders and MDD.
Keywords Bipolar-II  Bipolar-I  Hypomania 
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Introduction
The diagnostic classification of mood disorders is in a state
of flux. Three recent epidemiological studies from both
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Europe and the United States [1–3] which applied criteria
for bipolarity under the diagnostic threshold of DSM-IV
and ICD-10 have reported that over 40 % of persons with
major depressive episodes meet modified criteria for
bipolar disorders (BDs). With the exception of the Zurich
Study [4], most psychiatric epidemiological data were
collected with instruments tailored to the current diagnostic
manuals (e.g. the CIDI), which did not include sub-
threshold psychopathology.
In the diagnostic Bridge Study [BDs: Improving Diag-
nosis, Guidance, and Education] of 5,635 patients from 18
countries presenting for treatment with major depressive
episodes, the duration and symptoms of mania were
assessed using a descriptive, bottom-up approach which
allows testing of multiple definitions of bipolarity. A first
article of the Bridge Study compared the validity and
comorbidity of DSM-IV definitions of bipolarity with a
‘‘specifier’’ definition that adds increased activity as a gate
criterion and eliminates exclusions associated with use of
an antidepressant or other medical conditions [5]. A second
article assessed the validity of the diagnostic criteria for
mania/hypomania [6], that is, gate questions, duration of
episodes, number of symptoms and exclusions criteria.
This analysis compares patients with bipolar-I (BP-I) or
bipolar-II (BP-II) disorders with patients with major
depressive disorders (MDD) defined by DSM-IV versus
those defined by evidence-based bipolar specifier criteria
and consideration of concurrent comorbidities [1]. We also
consider the relevance of these results for the diagnosis and
classification of both BDs and MDDs, as well as their
implications for future studies and the clinical management
of these discrete disorders.
Methodology
Sample and assessment
The methodology of the Bridge Study has been described
in detail [5]. In summary, it is a cross-sectional diagnostic
investigation of 5,635 depressed patients conducted in 18
countries in Europe, Asia and North Africa between April
2008 and May 2009. Community- and hospital-based
psychiatrists recruited consecutively all adult patients
seeking treatment with a diagnosis of MDE according to
DSM-IV criteria [7]. At this evaluation, participating psy-
chiatrists completed a questionnaire on patients’ clinical
features, sociodemographic variables, diagnosis, medical
history, treatment and simultaneously comorbid psychiatric
disorders. Separate sections on hypomania/mania, and the
MINI International Neuropsychiatric Interview (MINI
DSM-IV) diagnostic interview [8], were applied. These
methods enabled a diagnosis of BD to be assigned, using
two different diagnostic algorithms: DSM-IV-TR and the
bipolarity specifier [5, 7]. Patients meeting all inclusion
criteria except for those for BP-I or BP-II were classed as
having MDD. Concurrent comorbid conditions were also
assessed by the MINI [8]. The study was carried out by
Sanofi-Aventis in co-operation with an advisory board.
Definitions of subgroups of mood disorders
Table 1 presents the DSM-IV definitions for BP-I and BP-
II disorders and the specifier definitions (S) for bipolarity
(BP-I-S and BP-II-S); the specifier criteria included
hypomanic episodes of 1 or more days, added increased
Table 1 Definitions of BP-I and BP-II disorders
DSM-IV BP-I BP-I-S
(specifier)
DSM-IV BP-II BP-II-S
(specifier)
Distinct period (days) 7? days 7? days 4? days 1? days
A.1. Elated/irritable mood ? ? ? ?
2. Increased activity or energy - ? - ?
B. Seven symptoms 3?/4? 3?/4? 3?/4? 3?/4?
C. Symptoms not meeting mixed episode Not assessed - Not assessed –
D. Marked impairment or hospitalisation
or psychotic
? ? - -
Marked impairment
or hospitalisation
-
E. Episode not due to somatic treatment ? - ? -
Criterion A2: new valid gate question (see Bridge Study paper on diagnostic criteria [6])
Criterion B: 3?/4? symptoms as in DSM-IV mania
Criterion C: not assessed in the Bridge Study
Criterion D: psychotic symptoms of mania were not assessed in the Bridge Study
Criterion E: not applied on the basis of results of paper on diagnostic criteria [6]
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activity/energy as a gate question in addition to elated
mood or irritability and did not apply the exclusion crite-
rion E of DSM-IV-TR (manic/hypomanic episode not due
to the direct physiological effects of a substance or a
general medical condition). The Bridge Study did not
assess concurrent mixed syndromes and psychotic symp-
toms of mania. All DSM-IV MDE patients without a BP-I
or BP-II diagnosis were classified as having MDD or
MDD-S, respectively.
Statistical methods
The association between an assigned diagnosis of MDD or
BD according to two sets of diagnostic concepts was
measured by odds ratios. As validators we used demo-
graphic, family history, illness course, as well as clinical
and comorbidity characteristics. Stepwise multiple logistic
regression analyses were then conducted on those variables
which proved significant in the bivariate analyses.
Results
BP-I and BP-II comparisons with MDD
Table 2 compares the three subgroups of major mood
disorders defined by the criteria listed in Table 1. DSM-IV
classified 12.2 % of MDE patients as having BP-I, 3.8 %
as having BP-II and 84.0 % as having MDD. In compari-
son, specifier (S) criteria identified 23.9 % as BP-I
(N = 1,348) and 23.1 % as having BP-II-S (N = 1,299),
resulting in identification of 53 % of the sample of all
patients with MDEs classified as having MDD-S.
Approximately two-thirds of patients were female, a pro-
portion that did not differ across diagnostic subgroups or
between DSM and bipolar S criteria.
Validity of BP-I-S and BP-II-S disorders
Table 2 lists a number of characteristics which are gener-
ally used as clinical validators for diagnostic concepts [9,
10]. For both diagnostic schemes (DSM-IV and specifier),
for variables which were significantly higher based on
bivariate odds ratios in BD than MDD, the BP-I/MDD
difference was larger than the BD-II/MDD difference.
Further, the magnitude of the odds ratio was consistently
greater between the groups diagnosed by the bipolar S
criteria. Proportions and associated odds ratios were gen-
erally similar for BP-I and BP-II; but a family history of
mania and the number of lifetime episodes C2 were both
greater for BP-I than BP-II subjects.
The specifier classification not only identified more
depressive patients as suffering from BP-I-S and BP-II-S
disorders but also yielded stronger differences between
bipolar and MDD-S disorders, therefore providing
improved validity compared with DSM-IV diagnoses.
Removing ‘‘sub-threshold’’ bipolars from the DSM-IV
MDD group led to substantive decreases in the rates of
bipolar characteristics among MDD-S patients. For exam-
ple, family history for mania decreased from 13.7 to 6.2 %.
Similar changes occurred among MDD-S defined patients
for illness course variables: age at onset, number of epi-
sodes, illness progression and seasonality.
Concurrent comorbidity of BP-I, BP-II and MD
disorders
Comorbidity patterns differed markedly between DSM-IV
BP-I and BP-II patients (Table 3): BP-II patients had sig-
nificantly greater comorbidity with most subgroups of
anxiety disorders, except panic disorder and social phobia.
Comorbidity rates for substance use disorders were similar
for BP-I and BP-II patients.
Compared to DSM-IV MDD, patients with DSM-IV BP-
I did not differ in comorbidity for any of the assessed other
disorders. Only suicide attempters were more common
among BP-I patients (35.6 vs. 27.1 %) among MDD
patients. DSM-IV BP-II patients showed significant
comorbidity with anxiety disorders (especially OCD, panic
with agoraphobia and social phobia) and binge eating but
not with suicide attempts (Table 2).
In contrast, applying the specifier criteria, patients with
BP-II-S showed significantly higher comorbidity rates than
BP-I-S in anxiety disorders except social phobia.
Compared to MDD-S patients with BP-I-S had higher
comorbidity with social phobia, OCD, binge eating,
ADHD, alcohol, substance use disorders and suicide
attempts. Similarly, BP-II-S patients had significantly
higher rates for each of the comorbid disorders including
binge eating but not eating disorder. Both bipolar specifier
groups also displayed significantly more frequent ADHD
and borderline personality disorders in comparison with the
MDD-S group.
In Table 4, we show gender differences for comorbidity
according to the specifier definitions; similar rates were
found for men and women (Table 4), but substance use
disorders were twice as high in men. Consistent with other
data, suicide attempt rates were somewhat higher in women
(BP-I-S 42.4 % and BP-II-S disorders 31.7 %) when
compared to 33.4 and 22.9 %, respectively, in men.
Overall, concurrent comorbidities were more sharply
demarcated between bipolar and MDD patients applying
the specifier classification than by DSM-IV classification.
Results from the more conclusive stepwise multiple
logistic regression analyses are shown in Table 5. Com-
pared to the DSM-IV TR diagnoses, the groups defined by
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specifier criteria varied both in size and in the odds ratios
for the chosen validators. Allocation of patients with DSM-
IV MDD to the bipolar specifier groups reduced the ORs
between BP-I and BP-II disorders; however, differences
between the MDD and bipolar subgroups increased or
remained stable. For example, a positive family history of
mania applying specifier criteria doubled the differences,
whereas differences in course characteristics remained
stable. In addition, several characteristics of bipolarity
(mood lability, mixed states and seasonality) tended to be
higher in the specifier groups. The same pattern of greater
differences applying specifier criteria held true for some
comorbid conditions: atypical depression, substance/alco-
hol use disorders and borderline personality disorders.
Discussion
These results from 5,635 patients evaluated by practising
psychiatrists in 18 countries provide pragmatic guidance
for clinicians and investigators regarding illness features
that fundamentally distinguish MDD, BP-I disorder and
BP-II disorder. BP-I patients compared with BP-II patients
had significantly higher rates of family history of mania/
hypomania, lifetime number of episodes, illness progres-
sion, seasonality of episodes, mood lability and mixed
episodes. A subset of concurrent anxiety comorbidities was
significantly more frequent among BP-II than BP-I
patients: GAD, panic disorder, OCD and anxiety disorder.
Most of these variables are sufficiently quantifiable and
reliable by standard clinical evaluation procedures that they
could serve as discriminators for formal diagnostic differ-
entiation between BP-I and BP-II forms of BD. The pre-
ponderance of anxiety disorders among BP-II versus BP-I
patients suggests that treatment approaches with BP-II
disorders should include specific anxiety focused proce-
dures. In contrast, non-anxiety comorbidities did not differ
between BP-I and BP-II disorders.
An important result of these analyses is that criteria that
distinguish BP-I and MDD are generally consistent with
those distinguishing BP-II and MDD, albeit more robust
for the BP-I versus MDD comparisons. This observation
supports the current DSM-IV-TR approach of applying the
same criteria for BP-I and BP-II diagnoses in contrast to
MDD diagnoses. The magnitude of BP-I versus MDD
differences was generally larger than that for BP-II versus
MDD.
Current concepts of MDDs are over-inclusive [11]. A
strength of DSM-IV-TR and bipolar specifier criteria
bipolar classifications is that they are not. In fact, specifier
classification yielded consistently stronger differences
between BP-I-S and BP-II-S compared to MDD-S disor-
ders than did DSM diagnoses. Therefore, one application ofT
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these results is to suggest a path forward for a more
homogeneous diagnosis MDD. In fact, the DSM-5 field
trials indicate that the reliability of BP-I and BP-II is larger
than that of MDD [12]. Such a process has important
clinical implications. It should lead to improved prognosis
and treatment response with antidepressants. Similarly, it
could contribute to improved testing of new treatments for
MDD through excluding enrolment of patients with BD
characteristics whose responses to the treatments confound
outcome assessments [13–15].
This analysis has uncommon strengths: including a large
sample supporting sub-analyses not generally possible in
research on differential diagnostic characterisation, and
evidence of generally similar results across countries and
cultures on all research questions for all analyses con-
ducted to date. The Bridge Study provides evidence-based
criteria to differentiate BP-I from BP-II disorders not
possible with DSM-IV-TR approaches, which limit the
applicable criteria to episode duration and functional
impairment during manic/hypomanic episodes. Our
detailed assessment of the elements of the hypomanic
syndrome allows a new, broader and more precise opera-
tional specifier definition for both BP-I and BP-II disorders.
This study provides the largest systematically diagnosed
group of patients experiencing (MDD-S) comprised of
2,988 patients. As hypothesised on the basis of the
epidemiological data, the reduction in the number of
patients meeting MDD-specifier criteria in comparison
with the DSM-IV MDD group reduced the rates of bipolar
characteristics among them. Family history of mania/
hypomania among first degree relatives was reduced from
13.7 % in DSM-MDD patients to 6.2 % in MDD-S
patients.
Although the specifier concept classified twice as many
MDE patients as BP-I patients, the validators for bipolarity
remained comparable between DSM-IV and specifier
concepts in terms of a history of mania among first degree
relatives, early onset, number of episodes, illness progres-
sion, duration of episodes and presence of free intervals.
The same is true when comparing DSM-IV BP-II with BP-
II-S patients, although the latter group is almost six times
larger.
We conclude from these findings that BP-I and BP-II
disorders defined by the specifier concept are both more
valid regarding their distinction from MDD than the cor-
responding DSM-IV groups.
One of the most striking and possibly heuristic findings
in these analyses is the high comorbidity of BP-II disorders
with all forms of anxiety disorders, in contrast to high
comorbidity limited to social phobia and OCD for BP-I
disorders, apparent using either the DSM-IV or specifier
diagnostic classification. Lifetime anxiety disorders, more
Table 4 Revised bipolar disorders—current comorbidity by gender
Groups Males Females
1 2 3 4 5 6
Diagnosis BP-I-S BP-II-S MDD-S BP-I-S BP-II-S MDD-S
N 551 455 986 786 835 1993
% % % % % %
Generalised anxiety disorder 6.8 10.6 8.1 8.6 10.6 8.9
Panic disorder 9.3 10.3 5.2 7.4 12.4 9.1
Panic disorder with agoraphobia 4.0 4.2 1.6 4.2 5.8 4.4
Social phobia 6.2 6.6 4.5 6.9 7.55 3.4
Obsessive–compulsive disorder 5.85 7.7 5.2 6.3 9.05 3.9
Any anxiety disordera 19.2 24.0 16.5 19.5 26.6 18.2
Eating disorder 0.4 0.4 0.3 1.0 1.7 1.0
Binge eating 5.6 3.1 2.4 8.9 10.7 4.4
Attention-deficit/hyperactive disorder 1.8 1.8 0.8 0.5 1.0 0.0
Alcohol use disorder 7.9 7.35 3.1 3.2 2.7 1.1
Substance use disorder 3.3 3.1 1.5 2.1 2.1 0.6
Substance or alcohol use disorder 9.65 9.64 4.3 4.8 4.1 1.6
Borderline personality disorder 12.8 11.3 5.5 16.8 15.2 4.6
Suicide attempts—lifetime 33.4 22.9 16.5 42.4 31.7 24.1
Clinically relevant values are marked in bold
a Includes GAD, panic, agoraphobia, social phobia and OCD
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than any other axis I condition, are highly comorbid with
BDs [4]. Panic disorder is much more prevalent in patients
with bipolar illness than in the general population; obses-
sive compulsive disorder is eight times more prevalent
[16]. Concomitant anxiety disorders are associated with
greater illness severity than bipolar patients without anxi-
ety disorders [4, 17]. Additionally, anxiety disorders are
predictive of poor outcomes, including lower likelihood of
recovery from depression, increased risk of relapse in
patients who recover from an acute episode and impaired
quality of life and role function [18–21]. Social phobia,
panic symptomatology and PTSD appear most associated
with impaired quality of life and time to recovered status
[18, 20]. None of these studies separately examined
comorbidities in bipolar-I and bipolar-II patients, nor
analysed discrete anxiety disorders separately. An epide-
miological study in Finland found mixed mania most
associated with anxiety symptomatology and poorer func-
tion [22].
A small number of studies have examined anxiety dis-
orders separately rather than collectively. The proportion of
patients in whom the onset of anxiety disorders preceded
hypomania was highest for social anxiety (95 %) compared
with half for obsessive–compulsive disorder and only one
quarter of patients for panic-agoraphobia [23]. The ante-
cedent appearance of social phobia/anxiety in childhood
among persons eventually diagnosed as having BDs indi-
cates that this component part of bipolar symptomatology
is a harbinger of syndromal BD, and suggests that such
bipolar subtypes are more severe. Although these earlier
studies support discrete, rather than agglomerated consid-
eration of anxiety disorder, none addressed the distinct
profile which we report.
Social phobia was elevated in BP-I versus MDD, but not
the other anxiety conditions. In contrast, BP-II shows ele-
vations across the spectrum of anxiety syndromes. Bipolar
patients with early illness displayed significantly more fear
of uncertainty and were shyer than patients with late onset
than either late onset bipolar or healthy controls [24].
Population-based phenotypic and factor-analytic studies
indicate two sub-components of anxiety disorders: fear
diagnoses and anxiety-misery disorders [25]. In sum, these
marked differences in patterns of comorbid anxiety suggest
that elements of underlying pathophysiology may be
involved. These differences may aid in better characteris-
ing pathophysiology as well as targeting intervention
strategies for BP-I and BP-II, respectively.
Both investigators and clinicians are disadvantaged
consequent to the historically low consideration of anxiety
in BD. Indeed, a primary reason that recent studies that
have reported linkages of BD with anxiety states, particu-
larly social anxiety, panic disorder and PTSD use methods
that assess for syndromal states, rather than focus on
domain, or dimensional methodologies, is that DSM-IV-
TR criteria for BD do not include any item for anxiety.
Additionally, no criterion for social withdrawal, which may
in part be consequent to social anxiety, is present for any
BD syndrome, including for depressive episodes in BD.
None of the most frequently used scales for mania has an
item for anxiety. Only one of the items on the most com-
monly used depression scale, the MADRS, deals with
anxiety. The MADRS has no item for reduced social
interest.
Comparing BP-I and BP-II disorders, the patterns of
comorbidity are relevant to clinical diagnosis and provide
new information about the burden of bipolarity. This study
assessed only concurrent, not lifetime comorbidity by the
MINI diagnostic interview. To our surprise, the DSM-IV
BP-I group did not differ much in their simultaneous
comorbidity from the MDD group. For instance, we
expected a clear association of BP-I disorders with sub-
stance use disorders, which was not present at all. Only
generalised anxiety disorders were less strongly associated
with BP-I than MDD, whereas suicide attempts were more
strongly associated with BP-I than with MDD. Of interest,
DSM-IV BP-II disorders were significantly associated with
the full spectrum of anxiety disorders (panic with agora-
phobia, social phobia, OCD) and also with binge eating.
The specifier BP-II-S group had consistently higher ORs
than did the DSM-IV classification, including significant
associations with all subgroups of anxiety disorders. In
contrast, the BP-I-S group was only associated with social
phobia and OCD but not with GAD or panic. On the other
hand, binge eating and substance use disorders were clearly
associated with BP-I-S and BP-II-S, as well as ADHD and
borderline personality disorder. The association of both BP
disorders with binge eating is interesting in the light of
research, using the hypomania checklist 32, on severely
obese patients seeking surgical treatment by Alciati et al.
[26]. Of further interest is the strong comorbidity of BP-I-S
and BP-II-S with borderline personality disorders (ORs 3.4
and 2.9, respectively). It is compatible with the results of
the follow-up study by Michael Stone [27]. It is also
noteworthy that the comorbidity patterns of BP-I-S and BP-
II-S were reproducible across gender.
This study has substantial strengths and some limita-
tions. The exceptionally large sample, standard assessment
battery applied by fully trained psychiatrists, and likelihood
that the lack of exclusionary criteria resulted in enrolment
of bipolar patients with the full spectrum of bipolar
symptomatology rather than a milder spectrum that too
often characterises clinical trials all constitute major
strengths. One limitation is that the study included only
treated MDE patients; it may not be generalisable to
untreated MDE subjects. It also did not assess psychotic
manic symptoms and concurrent mixed symptoms. Our
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results need confirmation by community studies assessing
brief episodes (1–3 days) of hypomania.
In conclusion, the broader specifier definitions of BP-I
and BP-II disorders yielded consistently valid and clini-
cally relevant results, particularly important given the high
rates of comorbid disorders in BD. The results provide
novel evidence that the forms of current comorbid anxiety
disorders differ substantially between bipolar-I and bipolar-
II disorders, and similarly between bipolar-I and bipolar-II
versus MDD patients.
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